The U.S. Food and Drug Administration has issued an emergency use authorization for the JYNNEOS vaccine, allowing healthcare providers to use the vaccine by intradermal injection for those 18 and older who are at high risk for monkeypox infection.

This will increase the total number of doses available for use by up to five-fold, according to the FDA.